OverviewSuggest Edit

AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs. The Company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C.
... Show more
TypePublic
Founded2013
HQNorth Chicago, US
Websiteabbvie.com
Employee Ratings3.8

Latest Updates

Employees (est.) (Nov 2018)30,000(+4%)
Job Openings488
Revenue (FY, 2016)$25.6 B(+13%)
Share Price (Feb 2019)$80.9

Key People/Management at AbbVie

Richard Gonzalez

Richard Gonzalez

Chairman of the Board and Chief Executive Officer
Carlos Alban

Carlos Alban

Executive Vice President, Commercial Operations
Timothy Richmond

Timothy Richmond

Senior Vice President, Human Resources​
Azita Saleki-Gerhardt

Azita Saleki-Gerhardt

Senior Vice President, Operations
Karen Hale

Karen Hale

Vice President, Chief Ethics and Compliance Officer
Wulff-Erik von Borcke

Wulff-Erik von Borcke

President, Pharmacyclics
Show more

AbbVie Office Locations

AbbVie has offices in North Chicago, Wyandotte, Cambridge, Worcester and in 12 other locations
North Chicago, US (HQ)
1 Waukegan Rd
Cambridge, US
200 Sidney St
Barceloneta, PR
PR-2
Show all (16)
Report incorrect company information

AbbVie Financials and Metrics

AbbVie Revenue

Embed Graph
View revenue for all periods
AbbVie's revenue was reported to be $25.64 b in FY, 2016 which is a 12.2% increase from the previous period.
USD

Revenue (Q3, 2018)

8.2b

Gross profit (Q3, 2018)

6.4b

Gross profit margin (Q3, 2018), %

77.7%

Net income (Q3, 2018)

2.7b

EBIT (Q3, 2018)

3.2b

Market capitalization (15-Feb-2019)

121.6b

Closing stock price (15-Feb-2019)

80.9

Cash (30-Sep-2018)

8.0b

EV

116.6b
AbbVie's current market capitalization is $121.6 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

18.8b20.0b22.9b25.6b

Revenue growth, %

6%15%12%

Cost of goods sold

4.6b4.4b4.5b5.8b

Gross profit

14.2b15.5b18.4b19.8b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

4.7b4.6b4.9b5.0b5.0b5.5b5.9b6.0b6.5b6.4b6.5b6.9b7.0b7.9b8.3b8.2b

Cost of goods sold

1.1b1.1b1.1b1.1b942.0m916.0m1.2b1.4b1.4b1.5b1.6b1.5b1.6b1.9b1.9b1.8b

Gross profit

3.6b3.5b3.8b3.9b4.1b4.6b4.8b4.6b5.0b4.9b4.9b5.4b5.4b6.0b6.3b6.4b

Gross profit Margin, %

77%76%77%78%81%83%80%77%78%77%75%78%77%76%77%78%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

9.6b8.3b8.4b5.1b

Accounts Receivable

3.9b3.7b4.7b4.8b

Inventories

1.2b1.1b1.7b1.4b

Current Assets

17.8b16.1b16.3b16.2b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

9.0b8.1b9.1b7.7b7.9b7.4b9.2b7.6b6.3b6.2b4.7b6.1b8.4b9.0b3.5b8.0b

Accounts Receivable

3.8b3.7b3.7b3.6b4.2b4.4b4.6b4.8b5.0b5.0b4.7b4.9b4.9b5.8b5.8b5.8b

Inventories

1.2b1.1b1.0b1.0b1.0b1.6b1.8b1.8b1.8b1.6b1.4b1.6b1.8b1.7b1.6b1.8b

Current Assets

16.5b17.3b17.8b17.6b15.4b16.9b17.9b16.6b16.8b16.3b15.5b17.0b18.9b20.4b13.8b18.5b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

4.1b1.8b5.1b6.0b

Inventories

(56.0m)(203.0m)(434.0m)(38.0m)

Accounts Payable

(426.0m)(193.0m)1.5b(1.2b)

Cash From Operating Activities

6.3b3.5b7.5b7.0b
Quarterly
USDY, 2018

EV/EBIT

36.9 x

Debt/Equity

-1 x

Financial Leverage

-22.7 x
Show all financial metrics

AbbVie Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Stem CentRxApril 28, 2016$5.80 b
Report incorrect company information

AbbVie Online and Social Media Presence

Embed Graph
Report incorrect company information

AbbVie News and Updates

Global Human Immunodeficiency Virus (HIV) Drugs Market 2019-2025 with AbbVie, Merck, Gilead Sciences, Bristol-Myers Squibb, Janssen & GSK Dominating

DUBLIN, Feb. 20, 2019 /PRNewswire/ -- The "Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 - 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts" report has been added to ResearchAndMarkets.com's offering. The global human immunodeficiency virus (HIV) drugs market...

AbbVie stock up 0.2% after FDA grants upadacitinib priority review status

Shares of AbbVie, Inc. were up 0.2% in premarket trade Tuesday after the company announced that the U.S. Food and Drug Administration had assigned priority review status to its new drug application for upadacitinib, a potential therapy for adult patients with moderate-to-severe rheumatoid arthritis…

Antibiotics And Antimycotics 2019 Global Market Key Players - Novartis, Bayer, Sanofi, Johnson & Johnson, Eli Lilly, Roche, GSK, Merck, AstraZeneca, AbbVie, Pfizer......

Antibiotics And Antimycotics – Global Market Growth, Opportunities, Analysis Of Top Key Players And Forecast To 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday

Testosterone Replacement Therapy Market Updates Till 2026 Explore By Top Players Pfizer, Inc., Bayer AG, Eli Lilly and Company, AbbVie, Inc.

Hypogonadism in men is primarily characterized by reduced concentration of serum testosterone, causing decreased libido, erectile dysfunction, loss of body and facial hair, decreased bone density, weakness, decreased lean body mass, increased body fat, fatigue and anemia. Posted via Industry Today. …

Bio-pharma Market to witness astonishing growth of 10.1% including key players Sanofi, Amgen, AbbVie, Merck, Biogen Idec

Advance Market Analytics, a global market research and consulting organization, have released a new study titled "Bio-pharma market - Global outlook to 2024". The study highlights influencing factors that are impacting or reinforcing market environment such as Government Policy, technological change…

Johnson Fistel, LLP Announces Investigations of AbbVie Inc., Macquarie Infrastructure Corporation, OPKO Health, Inc. and Uxin Limited; Investors Encouraged to Contact Firm

SAN DIEGO, Feb. 5, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against the following companies: AbbVie Inc. (NYSE: ABBV) [click here to join this action] Macquarie Infrastructure Corporation (NYSE:MIC) [click here to join this...
Show more
Report incorrect company information

AbbVie Company Life and Culture

Report incorrect company information

AbbVie Frequently Asked Questions

  • When was AbbVie founded?

    AbbVie was founded in 2013.

  • Who are AbbVie key executives?

    AbbVie's key executives are Richard Gonzalez, Carlos Alban and Timothy Richmond.

  • How many employees does AbbVie have?

    AbbVie has 30,000 employees.

  • What is AbbVie revenue?

    Latest AbbVie annual revenue is $25.6 b.

  • What is AbbVie revenue per employee?

    Latest AbbVie revenue per employee is $854.6 k.

  • Who are AbbVie competitors?

    Competitors of AbbVie include Johnson & Johnson, Roche and Novartis.

  • Where is AbbVie headquarters?

    AbbVie headquarters is located at 1 Waukegan Rd, North Chicago.

  • Where are AbbVie offices?

    AbbVie has offices in North Chicago, Wyandotte, Cambridge, Worcester and in 12 other locations.

  • How many offices does AbbVie have?

    AbbVie has 16 offices.